SCHEMBL3244835

SCHEMBL3244835

COc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(O)c2cc(Cl)ccc2Cl)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.65
TP53 P04637 1/20 0.65
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
PKM P14618 2/20 0.53
TSHR P16473 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
FLT1 P17948 1/20 0.52
FLT4 P35916 1/20 0.52
KDR P35968 1/20 0.52
LMNA P02545 7/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GAA P10253 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPK1 P28482 3/20 0.49
PGAM1 P18669 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249163 0.93 ALDH1A1 (0.61) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL4862691 0.89 ALDH1A1 (0.65) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3250469 0.88 ALDH1A1 (0.61) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3250923 0.84 ALDH1A1 (0.55) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3251279 0.84 KMT2A (0.48) ALDH1A1TP53TSHRFLT1FLT4
SCHEMBL3253215 0.84 ALDH1A1 (0.64) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3252030 0.83 ALDH1A1 (0.57) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3247097 0.83 KEAP1 (0.55) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3252136 0.83 KEAP1 (0.55) ALDH1A1TP53KEAP1NFE2L2PKM
SCHEMBL3247181 0.83 ALDH1A1 (0.62) ALDH1A1TP53KEAP1NFE2L2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 ALDH1A1 2179/4885TP53 4876/4885KEAP1 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.